Business Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Speciality Dialogues
    • Education Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Business Medical Dialogues
    • News
        • Financial Results
        • Hospitals & Diagnostics
        • IT / Health Venture
        • Implants / Devices
        • Insurance
        • Key Movement
        • Pharmaceuticals
        • Policy
        • Technology
        • pharma-news
    • blog
    LoginRegister
    Business Medical Dialogues
    LoginRegister
    • Home
    • News
      • Financial Results
      • Hospitals & Diagnostics
      • IT / Health Venture
      • Implants / Devices
      • Insurance
      • Key Movement
      • Pharmaceuticals
      • Policy
      • Technology
      • pharma-news
    • blog
    • Home
    • Latest News
    • Pharma giant Teva...

    Pharma giant Teva resists Israel PM on closure plan

    Written by Ruby Khatun Khatun Published On 2017-12-21T09:30:58+05:30  |  Updated On 16 Aug 2021 4:52 PM IST

    Jerusalem: Teva, the world's largest generic drug company, refused Tuesday to reconsider a decision to close its Jerusalem plant despite pressure from Prime Minister Benjamin Netanyahu, the government and group said.


    Teva will make 1,750 employees redundant in Israel as part of plans to slash 14,000 jobs worldwide over two years, according to the Histadrut trade union.


    The cuts would amount to more than a quarter of the Israeli drugmaker's global workforce of more than 55,000, of whom fewer than 7,000 work in Israel.


    At Sunday's weekly cabinet meeting, Netanyahu had said he would meet Teva's Danish boss Kare Schultz.


    A statement from his office said the premier aimed to "reduce the damage to workers, do everything possible to avoid the closure of the factory in Jerusalem, and ensure Teva remained an Israeli firm".


    At a meeting on Tuesday with Schultz, the government asked that the Jerusalem plant be kept open, "but the Teva chief refused", a statement from Netanyahu's office said.


    "He agreed to work with the government to find solutions for those employees who will be laid off," it added.


    In its own statement, the company quoted Schultz as saying that "Teva cannot accede to the prime minister's request".


    "In order for Teva to remain an Israeli company and continue to make a significant contribution to the Israeli economy, we must first save the company," it said.


    Thousands of Teva employees demonstrated outside the prime minister's office during Tuesday's meeting.


    Teva has been saddled with debt after its $40 billion acquisition of the generics arm of rival Allergan last year.


    The acquisition has been accompanied by low prices for generics, particularly in the United States, a major market.


    Teva expects to save $3 billion by the end of 2019 with the two-year restructuring plan.


    Schultz pledged to keep the company's headquarters in Israel, and thanked Netanyahu for "the support Teva has received from the Israeli government", its statement said.


    According to Histadrut, Teva has received $6.2 billion in tax reductions since 2006.


    The union said in a statement it would "continue to fight to limit the number of layoffs".


    Avi Gabbay, the leader of the opposition Labour party, attacked the prime minister over the Teva closure.


    "Kare Schultz has learned that Netanyahu only turns up for the photograph... he can keep on firing Teva employees," he said.

    closure plangeneric druggovernmentIsrael PMJerusalem plantKare Schultzpharma newsPrime Minister Benjamin NetanyahuresistsTeva
    Source : AFP

    Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

    Ruby Khatun Khatun
    Ruby Khatun Khatun
      Show Full Article
      Next Story
      Similar Posts
      NO DATA FOUND

      Popular Stories

      • Email: info@medicaldialogues.in
      • Phone: 011 - 4372 0751

      Website Last Updated On : 13 Oct 2022 5:14 AM GMT
      Company
      • About Us
      • Contact Us
      • Our Team
      • Reach our Editor
      • Feedback
      • Submit Article
      Ads & Legal
      • Advertise
      • Advertise Policy
      • Terms and Conditions
      • Privacy Policy
      • Editorial Policy
      • Comments Policy
      • Disclamier
      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

      © 2025 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      X
      We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok